Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer.

doi:10.1158/1078-0432.CCR-23-4005

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 14 Jun 2024

Harrold Emily, Keane Fergus, Walch Henry, Chou Joanne F, Sinopoli Jenna, Palladino Silvia, Al-Rawi Duaa H, Chadalavada Kalyani, Manca Paolo, Chalasani Sree, Yang Jessica, Cercek Andrea, Shia Jinru, Capanu Marinela, Bakhoum Samuel F, Schultz Nikolaus, Chatila Walid K, Yaeger Rona

Abstract excerpt

PURPOSE: Targeted therapies have improved outcomes for patients with metastatic colorectal cancer, but their impact is limited by rapid emergence of resistance. We hypothesized that an understanding of the underlying genetic mechanisms and intrinsic tumor features that mediate resistance to therapy will guide new therapeutic strategies and ultimately allow the prevention of resistance. EXPERIMENTAL DESIGN: We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosomal Instability

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Gene Amplification

Share to Molecular Targeted Therapy

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptor, ErbB-2

Source

Open in PubMed Open full text

Identifiers

PMID: 38502113
DOI: 10.1158/1078-0432.CCR-23-4005
PMCID: PMC11176917

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer.PMID 38502113Read ↗

Genomic Landscape, Targeted Therapies, and Mechanisms of Resistance in Molecularly Selected Metastatic Colorectal Cancer Patients.Semantic proximity Read ↗

Genomic Landscape, Targeted Therapies, and Mechanisms of Resistance in Molecularly Selected Metastatic Colorectal Cancer PatientsSemantic proximity Read ↗

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Genomic landscape of treatment refractory metastatic colorectal cancer.Semantic proximity Read ↗

Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just geneticsSemantic proximity Read ↗

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patientsSemantic proximity Read ↗

Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNASemantic proximity Read ↗

Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features.Semantic proximity Read ↗

Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance).Semantic proximity Read ↗

Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent EvolutionSemantic proximity Read ↗

Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers.Semantic proximity Read ↗

Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.